KR102770962B1 - Cd38 단백질 항체 및 이의 용도 - Google Patents

Cd38 단백질 항체 및 이의 용도 Download PDF

Info

Publication number
KR102770962B1
KR102770962B1 KR1020207026216A KR20207026216A KR102770962B1 KR 102770962 B1 KR102770962 B1 KR 102770962B1 KR 1020207026216 A KR1020207026216 A KR 1020207026216A KR 20207026216 A KR20207026216 A KR 20207026216A KR 102770962 B1 KR102770962 B1 KR 102770962B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
ser
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207026216A
Other languages
English (en)
Korean (ko)
Other versions
KR20200120937A (ko
Inventor
밍 엘브이
샤오란 딩
시웨이 미아오
빈 탄
주공 왕
Original Assignee
항저우 섬근 바이오테크 코포레이션, 엘티디.
섬근 엠에이비 (베이징) 바이오테크 코포레이션, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 항저우 섬근 바이오테크 코포레이션, 엘티디., 섬근 엠에이비 (베이징) 바이오테크 코포레이션, 엘티디. filed Critical 항저우 섬근 바이오테크 코포레이션, 엘티디.
Publication of KR20200120937A publication Critical patent/KR20200120937A/ko
Application granted granted Critical
Publication of KR102770962B1 publication Critical patent/KR102770962B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207026216A 2018-02-12 2019-02-11 Cd38 단백질 항체 및 이의 용도 Active KR102770962B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810144817.4A CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用
CN201810144817.4 2018-02-12
PCT/CN2019/074806 WO2019154421A1 (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Publications (2)

Publication Number Publication Date
KR20200120937A KR20200120937A (ko) 2020-10-22
KR102770962B1 true KR102770962B1 (ko) 2025-02-24

Family

ID=67547850

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207026216A Active KR102770962B1 (ko) 2018-02-12 2019-02-11 Cd38 단백질 항체 및 이의 용도

Country Status (11)

Country Link
US (1) US11713357B2 (cg-RX-API-DMAC10.html)
EP (1) EP3753955A4 (cg-RX-API-DMAC10.html)
JP (1) JP7333523B2 (cg-RX-API-DMAC10.html)
KR (1) KR102770962B1 (cg-RX-API-DMAC10.html)
CN (3) CN110144008B (cg-RX-API-DMAC10.html)
AU (1) AU2019218518B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020016271A2 (cg-RX-API-DMAC10.html)
CA (1) CA3091492C (cg-RX-API-DMAC10.html)
SG (1) SG11202007443XA (cg-RX-API-DMAC10.html)
TW (1) TWI818952B (cg-RX-API-DMAC10.html)
WO (1) WO2019154421A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
CN114075283A (zh) * 2020-08-12 2022-02-22 三生国健药业（上海）股份有限公司 结合人cd38的抗体、其制备方法和用途
CN114075285B (zh) * 2020-08-20 2023-05-30 瑞阳(苏州)生物科技有限公司 抗人cd38人源化单克隆抗体及其应用
CN116547307A (zh) * 2021-12-03 2023-08-04 南京维立志博生物科技有限公司 结合cd38的抗体及其用途
WO2024183634A1 (en) * 2023-03-09 2024-09-12 Norroy Bioscience Co., Ltd. Radiolabeled antibody conjugates and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
RU2402568C2 (ru) 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2342220B1 (en) * 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10533057B2 (en) 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
CR20170526A (es) * 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP7027321B2 (ja) * 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
KR102770106B1 (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
US11780930B2 (en) 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody

Also Published As

Publication number Publication date
US11713357B2 (en) 2023-08-01
WO2019154421A1 (zh) 2019-08-15
JP2021512652A (ja) 2021-05-20
RU2020129820A (ru) 2022-03-14
KR20200120937A (ko) 2020-10-22
BR112020016271A2 (pt) 2020-12-15
RU2020129820A3 (cg-RX-API-DMAC10.html) 2022-03-14
JP7333523B2 (ja) 2023-08-25
SG11202007443XA (en) 2020-09-29
US20210024645A1 (en) 2021-01-28
AU2019218518B2 (en) 2025-07-10
CN114835809A (zh) 2022-08-02
EP3753955A1 (en) 2020-12-23
CN111712521B (zh) 2022-03-15
EP3753955A4 (en) 2021-12-08
AU2019218518A1 (en) 2020-10-01
CA3091492A1 (en) 2019-08-15
TWI818952B (zh) 2023-10-21
CA3091492C (en) 2023-10-10
CN111712521A (zh) 2020-09-25
CN110144008B (zh) 2021-03-19
TW201934577A (zh) 2019-09-01
CN110144008A (zh) 2019-08-20

Similar Documents

Publication Publication Date Title
AU2019228474B2 (en) PD-1 agonist antibodies and uses thereof
KR101439719B1 (ko) Ｃｓｆ-１ｒ에 대한 항체
CN110144008B (zh) Cd38蛋白抗体及其应用
CN110545844A (zh) 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
WO2018029367A1 (en) Combination therapy for cancer
KR20110050541A (ko) 항-ｃｄ５ 항체
CN110540592B (zh) 结合axl蛋白的抗体及其应用
RU2776795C2 (ru) Антитела к белку cd38 и их применение
HK40006534B (zh) Cd38蛋白抗体及其应用
HK40006534A (en) Cd38 protein antibody and its application
US20230250186A1 (en) Cd38 protein antibody and application thereof
HK40029523B (en) Cd38 protein antibody and application thereof
HK40034156A (en) Cd38 protein antibody and application thereof
HK40052906B (en) Anti-cd269 antibody-drug conjugate (adc), anti-cd269 antibody and use thereof
HK40029523A (en) Cd38 protein antibody and application thereof
WO2024245441A1 (zh) 靶向cd39的抗原结合蛋白及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200910

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240618

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250207

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250217

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250218

End annual number: 3

Start annual number: 1

PG1601 Publication of registration